• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Do immune checkpoint inhibitors increase sensitivity to salvage chemotherapy?

作者信息

Saleh Khalil, Khalifeh-Saleh Nadine, Kourie Hampig Raphaël, Nasr Fadi, Chahine Georges

机构信息

Hematology-Oncology Department, Faculty of medicine, Saint Joseph University, Beirut, Lebanon.

出版信息

Immunotherapy. 2018 Mar;10(3):163-165. doi: 10.2217/imt-2017-0153.

DOI:10.2217/imt-2017-0153
PMID:29370724
Abstract
摘要

相似文献

1
Do immune checkpoint inhibitors increase sensitivity to salvage chemotherapy?免疫检查点抑制剂会增加对挽救性化疗的敏感性吗？
Immunotherapy. 2018 Mar;10(3):163-165. doi: 10.2217/imt-2017-0153.
2
Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen.铂类方案难治的转移性尿路上皮癌患者在接受免疫检查点抑制剂治疗后对顺铂再激发出现意外反应。
Eur J Cancer. 2018 Nov;104:236-238. doi: 10.1016/j.ejca.2018.09.002. Epub 2018 Oct 11.
3
Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy.建立抗程序性死亡蛋白1（PD-1）免疫检查点抑制剂治疗的辅助诊断方法。
Ann Oncol. 2016 Oct;27(10):1966-9. doi: 10.1093/annonc/mdw288. Epub 2016 Aug 8.
4
Do immune-related adverse events correlate with response to immune checkpoint inhibitors?免疫相关不良事件与免疫检查点抑制剂的反应相关吗？
Immunotherapy. 2019 Mar;11(4):257-259. doi: 10.2217/imt-2018-0201.
5
Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.介入治疗联合免疫检查点抑制剂：免疫治疗时代癌症治疗的新机遇。
Cancer Treat Rev. 2019 Mar;74:49-60. doi: 10.1016/j.ctrv.2018.08.006. Epub 2018 Aug 20.
6
Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy.抗 CD137 和 PD-1/PD-L1 抗体走向临床协同作用。
Clin Cancer Res. 2017 Sep 15;23(18):5326-5328. doi: 10.1158/1078-0432.CCR-17-1799. Epub 2017 Aug 8.
7
Biomarkers of response to PD-1/PD-L1 inhibition.PD-1/PD-L1抑制反应的生物标志物。
Crit Rev Oncol Hematol. 2017 Aug;116:116-124. doi: 10.1016/j.critrevonc.2017.06.001. Epub 2017 Jun 9.
8
Dissecting the mechanisms of immune checkpoint therapy.剖析免疫检查点疗法的机制。
Nat Rev Immunol. 2020 Feb;20(2):75-76. doi: 10.1038/s41577-020-0275-8.
9
Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer.在接受 PD-1/PD-L1 抑制剂治疗的非小细胞肺癌患者中，挽救性化疗的反应率增加。
J Thorac Oncol. 2018 Jan;13(1):106-111. doi: 10.1016/j.jtho.2017.10.011. Epub 2017 Oct 31.
10
Immune checkpoint inhibitors in advanced non-small cell lung cancer.免疫检查点抑制剂在晚期非小细胞肺癌中的应用。
Cancer. 2018 Jan 15;124(2):248-261. doi: 10.1002/cncr.31105. Epub 2017 Dec 6.

引用本文的文献

1
Prognostic factors of second-line nivolumab monotherapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study for 184 cases.二线纳武利尤单抗单药治疗不可切除或转移性食管癌的预后因素：184 例多机构队列研究。
J Gastroenterol. 2024 Nov;59(11):979-985. doi: 10.1007/s00535-024-02141-8. Epub 2024 Aug 17.
2
First‑line programmed cell death 1 inhibitor plus chemotherapy vs. standard treatment in patients with recurrent or metastatic oral squamous cell carcinoma: A retrospective cohort study.一线程序性细胞死亡1抑制剂联合化疗与标准治疗用于复发性或转移性口腔鳞状细胞癌患者的疗效比较：一项回顾性队列研究
Oncol Lett. 2024 Jun 3;28(2):352. doi: 10.3892/ol.2024.14486. eCollection 2024 Aug.
3
Immunotherapeutic and their immunological aspects: Current treatment strategies and agents.
免疫疗法及其免疫学方面：当前的治疗策略与药物
Natl J Maxillofac Surg. 2022 Sep-Dec;13(3):322-329. doi: 10.4103/njms.njms_62_22. Epub 2022 Dec 10.
4
Radiotherapy, Chemotherapy and Immunotherapy-Current Practice and Future Perspectives for Recurrent/Metastatic Oral Cavity Squamous Cell Carcinoma.放射治疗、化学治疗和免疫治疗——复发性/转移性口腔鳞状细胞癌的当前实践与未来展望
Diagnostics (Basel). 2022 Dec 29;13(1):99. doi: 10.3390/diagnostics13010099.
5
Programmed Cell Death-Ligand 1 in Head and Neck Squamous Cell Carcinoma: Molecular Insights, Preclinical and Clinical Data, and Therapies.程序性细胞死亡配体 1 在下咽鳞状细胞癌中的作用：分子见解、临床前和临床数据以及治疗方法。
Int J Mol Sci. 2022 Dec 6;23(23):15384. doi: 10.3390/ijms232315384.
6
Is chemoimmunotherapy a game changer in the treatment of locally advanced head and neck squamous cell carcinoma?化学免疫疗法是否会改变局部晚期头颈部鳞状细胞癌的治疗格局？
Clin Case Rep. 2021 Sep 22;9(9):e04793. doi: 10.1002/ccr3.4793. eCollection 2021 Sep.
7
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort.一线免疫治疗进展后，接受挽救性化疗或帕博利珠单抗治疗，联合或不联合局部消融治疗，用于PD-L1≥50%的晚期非小细胞肺癌患者的疗效：来自欧洲队列的真实世界数据
J Thorac Dis. 2019 Dec;11(12):4972-4981. doi: 10.21037/jtd.2019.12.23.
8
[Treatment of head and neck squamous cell carcinoma recurrences and distant metastases : Highlights of the 2019 ASCO Meeting].[头颈部鳞状细胞癌复发与远处转移的治疗：2019年美国临床肿瘤学会会议要点]
HNO. 2019 Dec;67(12):898-904. doi: 10.1007/s00106-019-00773-4.